


**Supplementary Table 1 Comparing screening strategies for latent TB, *n* (%)**

| <b>Strategy of screening</b> | <b>LTB patients in group</b> | <b>LTB patients identified by the strategy</b> |
|------------------------------|------------------------------|--|
| Standard screening           | 1/77 (1.29 %)                | 1/1 (100%)                                     |
| Incomplete screening         | 11/54 (20.37%)               | 9/11(81.81%)                                   |
| Diligent screening           | 18/125 (14.40%)              | 18/18 (100%)                                   |
| Limited screening            | 22/253 (8.69%)               | 20/22 (90.90%)                                 |
| Immunodiagnostic screening   |                              |  |
| Both                         | 24/208 (11.53%)              | 16/24 (66.66%)                                 |
| Either                       | 40/353 (11.33%)              | 30/40 (75.0 %)                                 |
| Neither                      | 0/25                         | Nil  |
| CT chest based screening     | 28/242 (11.57%)              | 11/28 (39.28%)                                 |

Graphical abstract

**Latent tuberculosis screening for inflammatory bowel disease in TB endemic region remains porous and suboptimal- A multicentre study**



**LTB screening Compliance**



IGRA 79%



Mantoux 69%



CXR 79%



CT chest 64%

**Standard screening 58%**  
(TST + IGRA + CXR)


**Diligent screening 33%**  
(TST + IGRA + CT Chest)

**Annual screening -27%**

**Latent TB- 11%**

**Active TB-4.5%**

**ADVANCED THERAPY**



IFX ADA Vedo Tofa

**Conclusion**

**Suboptimal compliance and no safe advanced therapy**